TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05131893
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT05269615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste and smell. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.
Study: NCT06455969
Drug: Testosterone gel (AndroGel 5g)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).
Study: NCT06455969
Drug: Testosterone gel (AndroGel 1.25g)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).
Study: NCT06455969
Drug: Estradiol / Levonorgestrel Transdermal System [Climara Pro]
Normalized name: estradiol / levonorgestrel Transdermal System [Climara Pro]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.
Study: NCT06455969
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.
Study: NCT06463743
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05080218
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hold SQ TNFi x 2 weeks at time of COVID booster
Study: NCT05596227
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be injected during the induction of anesthesia (1-1.5 mg/kg)
Study: NCT05034952
Drug: HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration.
Study: NCT05034952
Drug: Placebo (matched to VX-548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-548 for oral administration.
Study: NCT05034952
Drug: Placebo (matched to HB/APAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT05351437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT05122702
Drug: modified Shenling Baizhu San
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified Shenling Baizhu San granules, twice daily for 12 weeks.
Study: NCT05031026
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline infusion as a placebo
Study: NCT05553938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin matched placebo tablet
Study: NCT05468073
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-cutaneous injections of placebo (NaCl) Induction phase: 5 consecutive days. A week break. Maintenance phase: once a week during 16 weeks.
Study: NCT05948865
Drug: CPO301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous injection
Study: NCT05567562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06222879
Drug: HRS-8080; SHR-A2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive HRS-8080 and SHR-A2009
Study: NCT06222879
Drug: SHR-A2009; SHR-1316
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SHR-A2009 and SHR-1316
Study: NCT05246865
Drug: oral androgen challenge with dehydroepiandrosterone (DHEA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral androgen challenge is a safe and well-validated means of studying the androgen generation profiles of different study groups.
Study: NCT04977180
Drug: Cardioprotection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive beta blocker (metoprolol or carvedilol) and an ACE inhibitor (lisinopril)
Study: NCT05279703
Drug: Epinephrine 0.03
Normalized name: epinephrine 0.032 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine infusion rate of 0.03 mcg/kg/min
Study: NCT05279703
Drug: Epinephrin 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine infusion rate of 0.02 mcg/kg/min
Study: NCT05279703
Drug: Epinephrin 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine infusion rate of 0.01 mcg/kg/min
Study: NCT06289205
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment
Study: NCT06431971
Drug: Talineuren
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talineuren infusion weekly
Study: NCT06431971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion weekly
Study: NCT06536101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral dose
Study: NCT05021640
Drug: Placebo for DCR-AUD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline for injection
Study: NCT06067191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04353661
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin will be administered orally.
Study: NCT04911751
Drug: KBL697
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule BID of KBL697 or Placebo
Study: NCT06124001
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.
Study: NCT04911751
Drug: KBL697
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 capsules BID of KBL697 or Placebo
Study: NCT04962958
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Study: NCT06504732
Drug: IAH0968
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
Study: NCT05702827
Drug: Bupivacaine-Meloxicam
Normalized name: bupivacaine-meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive standard of care but the study arm will also receive Bupivacaine-Meloxicam in addition.
Study: NCT05140148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pills
Study: NCT05813275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration at bedtime
Study: NCT05049083
Drug: New Process SHR2554 tablet、Former Process SHR2554 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8
Study: NCT05049083
Drug: Former Process SHR2554 tablet、New Process SHR2554 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
Study: NCT06452654
Drug: Comirnaty Injectable Product
Normalized name: Comirnaty Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination
Study: NCT05278351
Drug: Third-line regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridinetipiracil or Regorafenib or Fruquintinib
Study: NCT06528457
Drug: ISLA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISLA101 is an oral gelatin capsule containing 100 mg of fenretinide (N-\[4-Hydroxyphenyl\]retinamide, mw 391.56) dissolved in corn oil and polysorbate 80. ISLA101 capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
Study: NCT06528457
Drug: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.
Study: NCT05808634
Drug: BA3182
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
Study: NCT05849480
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).
Study: NCT05263869
Drug: MRG002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated intravenously
Study: NCT05242146
Drug: GB5121
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing GB5121
Study: NCT06322056
Drug: Standard control of SBP and intensive control of LDL-C
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 70 mg/dL.
Study: NCT06322056
Drug: Standard control of SBP and standard control of LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participants would be assigned to a SBP target of less than 140 mmHg and a LDL-C target of less than 100 mg/dL.
Study: NCT05281328
Drug: CAM2029
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection using a pre-filled pen
Study: NCT05281328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection using a pre-filled pen
Study: NCT05785819
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching VLX-1005
Study: NCT05867589
Drug: 68Ga/18F-FAPI-04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.
Study: NCT06312813
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1ml propylene glycol
Study: NCT04990232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ml (10ml for patients with creatinine clearance lower than 30ml/min) intravenous (IV) 0.9% saline (N/S) three times daily (every eight hours) for 15 days and 0.5 ml subcutaneous (sc) 1ml 0.9% N/S every other day for a total of 15 days
Study: NCT06568627
Drug: EscharEx (EX-03)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
Study: NCT06568627
Drug: Placebo (Gel vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Study: NCT04355572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to placebo daily
Study: NCT06342310
Drug: RE104 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, subcutaneous dose of RE104 for Injection
Study: NCT04316910
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.
Study: NCT05203341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT00000973
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05722964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo，Intravenous injection
Study: NCT05726318
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoaxole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
Study: NCT05641246
Drug: (VOLTAREN®) Emulgel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: (VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has a cooling effect.
Study: NCT05950646
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be infused at a rate of 0.01 ml/ kg/h from 8 pm in the night before surgery until 8 am in the third morning after surgery.
Study: NCT05971732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, patients will receive the equivalent number of normal saline injections.
Study: NCT06332872
Drug: 4% dimenticone liquid gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical formulation (liquid gel) only 1 application
Study: NCT04687514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: first week 1x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe, following weeks 2x0.5 ml physiological saline (0.9% sodium chloride) injection s.c. via syringe once weekly for 3 further weeks.
Study: NCT06067425
Drug: SAR442501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection; Subcutaneous injection
Study: NCT05900466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablets once daily in the morning for 8 weeks
Study: NCT05391789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
Study: NCT04381468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80
Study: NCT06210360
Drug: LV
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/m² on Day 1 of a 14 day cycle
Study: NCT05500222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: randomized matching placebo
Study: NCT05761795
Drug: IVMED 85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drop
Study: NCT05761795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drop
Study: NCT05263999
Drug: EQ001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQ001 Placebo
Study: NCT04184882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06031389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
Study: NCT04985344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.
Study: NCT06647940
Drug: R-CHOP Protocol
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Study: NCT05440851
Drug: Usual care without routine corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
Study: NCT05440851
Drug: Usual care without extending corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
Study: NCT05440851
Drug: 4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
Study: NCT05731973
Drug: Intercostal nerve block (single shot bupivacaine (1.25 mg/ml))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single shot bupivacaine (1.25 mg/ml) intercostal nerve blocks are placed just anterior to the side of the cryoablation.
Study: NCT05702229
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2
Study: NCT05702229
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1
Study: NCT05702229
Drug: AZD7789
Approvals — FDA: no, EMA: no, PMDA: no
Description: an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
Study: NCT05702229
Drug: AZD0901
Approvals — FDA: no, EMA: no, PMDA: no
Description: an anti Claudin18.2 ADC; IV infusion
Study: NCT05702229
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral take, Q3W
Study: NCT05784363
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl).
Study: NCT05784363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% NaCl.
Study: NCT05860270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will receive placebo 2 capsules per day.
Study: NCT05778591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo.
Study: NCT04671472
Drug: NPC-09
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be administered by the oral route with the same manner
Study: NCT04671472
Drug: NPC-09 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be administered by the oral route with the same manner
Study: NCT04764474
Drug: HMPL-306
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally QD in a 28-day continuous dosing treatment cycle
Study: NCT06557473
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl IV 2 µg/kg for GA induction
Study: NCT05226013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06224387
Drug: CTS2190 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
Study: NCT06437431
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of glenzocimab is 0.9% NaCl for IV administration. It is supplied for clinical trial use in vials of 50 mL. Two vials of placebo should be administered concomitantly for eligible patients. The administration scheme will be the same as in the experimental arm.
Study: NCT06385925
Drug: TSN1611
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Study: NCT05570058
Drug: RXC007
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXC007 will be administered in the form of oral capsules at 3 potential dose levels: 20 mg, 50mg and 70 mg in 5 cohorts. 12 patients of cohorts 1, 2 and the Expansion cohort will receive RXC007. The Dosage regimen is BID or QD.
Study: NCT04475198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Dextrose Injection
Study: NCT05570058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered in the form of oral capsules at each dose level to 4 of the 16 participants within cohorts 1, 2 and the Expansion cohort. The Dosage regimen is BID or QD
Study: NCT01010724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06401317
Drug: Saline Hypertonic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided intra-articular injection of 0.25ml of 0.9% saline solution.
Study: NCT05382767
Drug: CKDB-501A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle Spasticity
Study: NCT05382767
Drug: Botox®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle Spasticity
Study: NCT04641338
Drug: Fixed dose combination Dipyrone and Codeine
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
Study: NCT04641338
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg codeine every 6 hours if necessary.
Study: NCT04911075
Drug: 85% TCA Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: * TCA is an acetic acid analogue solution (CCl3COOH) which is formed from the reaction of acetic acid (CH3COOH) with chlorine (3Cl2).~* High concentrations (85 percent) of this solution can penetrate deeply into the epidermis-dermis layer and cause cells necrosis.~* This solution (1-2 milliliter) will be applied to participants cervical tissue (ectocervix and endocervix) using cotton swab for 1-3 minutes.
Study: NCT06139796
Drug: DRV/r FDC (120/20mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of DRV/r FDC (120/20mg) as part of antiretroviral therapy (ART) with an Optimized Background Therapy (OBT)